Glecaprevir/Pibrentasvir + Losartan = Unknown or no reaction

Effect on Concentration

Glecaprevir/Pibrentasvir
No change
Applies within class?
No
Losartan
Increase
Applies within class?
No

Pharmacologic Effects

Glecaprevir/Pibrentasvir
Effect
N/A
Applies within class?
No
Losartan
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 20-Jul-2018

Summary

Sources

Glecaprevir/Pibrentasvir versus Losartan ^

Study Design

This was an open-label one-sequence crossover study involving n=12 health adult subjects. Each received a single dose of losartan 50mg alone or in combination with glecaprevir/pibrentasvir 300mg/120mg QD. Intensive blood sampling for determination of metabolite and glecaprevir/pibrentasvir concentrations was done. The effects of glecaprevir/pibrentasvir on the PK of losartan and vice versa was analyzed.

Study Results

Exposures were higher for losartan increase in Cmax 151% and AUC 56% when administered with multiple doses of glecaprevir/pibrentasvir, relative to losartan alone. Exposures of glecaprevir/pibrentasvir were similar regardless of if losartan was onboard or not. This combination was generally well tolerated, with no serious adverse events being reported.

Study Conclusions

Per the authors, clinically significant PK interactions between glecaprevir/pibrentasvir and losartan are not anticipated. No dose adjustment is required when glecaprevir/pibrentasvir and losartan are coadministered.

References

Kosloski. Drug-drug interactions between direct acting antivirals abt-493 and abt-530 with angiotensin ii receptor blockers (valsartan or valsartan) [abstract]. American Association For The Study Of Liver Diseases. Boston, MA, USA. ; November 2016.